Cargando…

Potential benefits of pharmacist intervention in the detection and therapy of atrial fibrillation

Detalles Bibliográficos
Autor principal:	Adam, Lauren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Departments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282919/ https://www.ncbi.nlm.nih.gov/pubmed/34345315 http://dx.doi.org/10.1177/17151635211019963

Ejemplares similares

Evaluation of Diabetes Education and Pharmacist Interventions in a Rural, Primary Care Setting
por: Meade, Lisa T., et al.
Publicado: (2018)

Pharmacists continue to protect communities during COVID-19
por: Worthington, Lindsey, et al.
Publicado: (2020)

Pharmacists continue to protect communities during COVID-19
por: Carico, Ronald
Publicado: (2020)

Pharmacists continue to protect communities during COVID-19
por: Grabenstein, John D.
Publicado: (2020)

Tommy Ricketts, VC: Newfoundland and Labrador war hero and pharmacist
por: Grant, Christopher C. W.
Publicado: (2021)

Virtual Self-Management Has Potential Benefits and Challenges: A Response to a Letter to the Editor
por: Miller, Jordan, et al.
Publicado: (2021)

Pharmacists’ Impact on Glycemic Control Among Surgical Patients at a Large Academic Institution
por: Nguyen, Cynthia T., et al.
Publicado: (2016)

Pharmacists detecting atrial fibrillation in general practice: a qualitative focus group study
por: Savickas, Vilius, et al.
Publicado: (2020)

Legumes: Health Benefits and Culinary Approaches to Increase Intake
por: Polak, Rani, et al.
Publicado: (2015)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
por: Fitzgerald, P., et al.
Publicado: (2020)

The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways
por: Leblanc, Kori, et al.
Publicado: (2021)

Brief Literature Review: The Potential of Diabetes Technology to Improve Sleep in Youth With Type 1 Diabetes and Their Parents: An Unanticipated Benefit of Hybrid Closed-Loop Insulin Delivery Systems
por: Cobry, Erin C., et al.
Publicado: (2019)

Defining the benefit: Cardioversion of persistent atrial fibrillation
por: Nedios, Sotirios, et al.
Publicado: (2021)

Atrial fibrillation in the elderly
por: Franken, Roberto A., et al.
Publicado: (2012)

Supraventricular Tachycardia With Underlying Atrial Flutter in a Diabetic Ketoacidosis Patient
por: Faruqi, Taha A., et al.
Publicado: (2015)

Pharmacist management of atrial fibrillation in UK primary care: a qualitative study
por: Al-Arkee, Shahd, et al.
Publicado: (2022)

Does Your Patient Need Diabetic Therapeutic Footwear? (Where Benefit, Evidence, and Bureaucracy Collide)
por: Brunner, John E.
Publicado: (2015)

Improving Cost-Effectiveness of and Outcomes From Drug Therapy in Patients With Atrial Fibrillation in Managed Care: Role of the Pharmacist
por: Johnson, Samuel G.
Publicado: (2009)

Benefits of prescribing low-dose digoxin in atrial fibrillation
por: Rosca, Ciprian Ilie, et al.
Publicado: (2021)

Regional implementation of atrial fibrillation screening: benefits and pitfalls
por: Theunissen, Luc J H J, et al.
Publicado: (2022)

The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway
por: Calvert, Peter, et al.
Publicado: (2023)

Inflammation, atrial fibrillation, and the potential role for colchicine therapy
por: Varghese, Bibin, et al.
Publicado: (2021)

Augmenting Telemonitoring Interventions by Targeting Patient Needs in a Primarily Hispanic Underserved Population
por: Shane-McWhorter, Laura, et al.
Publicado: (2016)

Smart detection of atrial fibrillation(†)
por: Krivoshei, Lian, et al.
Publicado: (2017)

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease
por: Lee, So-Ryoung, et al.
Publicado: (2022)

Ischaemic stroke in the absence of documented atrial fibrillation: is there who could benefit from anticoagulant therapy?
por: Vassiliki’ Coutsoumbas, Gloria, et al.
Publicado: (2022)

Results of the Epidemiology of Diabetes Interventions and Complications Trial
por: Wright, Eugene E.
Publicado: (2015)

Physicians’ Mutual Benefit Associaton of Texas
Publicado: (1889)

Nonpharmacological Therapies for Atrial Fibrillation
por: Caldwell, Jane C., et al.
Publicado: (2011)

Surgical Therapy of Atrial Fibrillation
por: Haensig, Martin, et al.
Publicado: (2012)

Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol
por: Veale, Emma L, et al.
Publicado: (2018)

Evaluation of an Education Intervention in Hispanic Women at Risk for Gestational Diabetes Mellitus
por: Hieronymus, Laura, et al.
Publicado: (2016)

Automated Atrial Fibrillation Detection with ECG
por: Wei, Ting-Ruen, et al.
Publicado: (2022)

Clinical Implications of Device-Detected Atrial Fibrillation in Cardiac Resynchronization Therapy
por: Yoon, Minjae, et al.
Publicado: (2023)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
por: Atterman, Adriano, et al.
Publicado: (2021)

Evaluating the benefits of home-based management of atrial fibrillation: current perspectives
por: Sheikh, Azfar B, et al.
Publicado: (2016)

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Improving the Detection of Foot Abnormalities in Patients With Diabetes
por: Gallman, Ellen C., et al.
Publicado: (2017)

Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation
por: Cho, Min Soo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ut4m33pn7qj7ocol7lqldcpfmq